The efficacy of a 40-mg extended-release formulation of cisapride in the treatment of patients with gastro-oesophageal reflux

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 1, 2000, Pages 113-122

  Katschinski, M ^a,b   Schirra, J ^a   Arnold, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Dept of Gastroenterol and E ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDING; SUPINE POSITION;

ADOLESCENT; ADULT; AGED; CISAPRIDE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED;

EID: 0033978492     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00672.x     Document Type: Article

References (34)

1. 1 Revicki DA, Wood M, Maton PM, Sorensen S. The impact of gastroesophageal reflux disease on health related quality of life. Am J Med 1998; 104: 252-8.
2. 2 Galmiche JP. Janssens J. The pathophysiology of gastrooespohageal reflux disease: an overview. Scand J Gastroenterol 1995; 30: 7-18.
3. 3 Ceccatelli P. Janssens J, Vantrappen G, Cuchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631-5.
4. 4 Maddern GJ. Jamieson GG, Myers JC, et al. Effect of cisapride on delayed gastric emptying in gastroesophageal reflux disease. Gut 1991; 32: 470-1.
5. 5 Galmiche JP, Freytag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35: 649-55.
6. 6 Paterson WG, Wang H, Beck IT. The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH-metry study. Am J Gastroenterol 1997; 92: 226-30.
7. 7 Butler J. Farrell C, Tynan S. A study in healthy volunteers to evaluate the steady-state bioequivalence of the Elan 40-mg cisapride tartrate o.d. formulation relative to Prepulsid 10 mg q.i.d. and the effect of coadministration of 20 mg omeprazole (Losec) on the bioavailability of the Elan 40-mg cisapride tartrate o.d. formulation. Elan Pharmaceutical Technologies and Janssen Research Foundation, Clinical Research Report (ELAN-1096002), September 1997.
8. 8 Richter JE, Bradley LA, De Meester TR, Wu WC. Normal 24 hour ambulatory esophageal pH-values. Influence of study center, pH-electrode. age and gender. Dig Dis Sci 1992; 37: 849-56.
9. 9 van Peer A, Verlinden M, Woestenborghs R, et al. Clinical pharmacokinetics of cisapride. In: Johnson AG, Lux G, eds. Progress in the Treatment of Gastrointestinal Motility Disorders: the Role of Cisapride. Amsterdam: Excerpta Medica, 1988: 23-9.
10. 10 Wang H, Beck IT, Paterson WG. Reproducibility and physiological characteristics of 24-hour ambulatory esophageal manometry/pH-metry. Am J Gastroenterol 1996; 91: 492-7.
11. 11 Johnsson F. Joelsson B. Reproducibility of ambulatory oesophageal pH monitoring. Gut 1988; 29: 886-9.
12. 12 Tonini M, Galligan JJ, North RA. Effects of cisapride on cholinergic neurotransmission and propulsive motility in guinea pig ileum. Gastroenterology 1989; 86: 1257-64.
13. 13 Taniyama K, Nakayama S, Takeda K, et al. Cisapride stimulates motility of the intestine via the 5-hydroxy-tryptamin receptors. J Pharmacol Exp Ther 1991; 258: 1098-104.
14. 14 Toussaint J. Gossuin A, Deruyttere M, Hublé F, Devis G. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280-5.
15. 15 Richter JE. Long JF. Cisapride for gastroesophageal reflux disease. A placebo-controlled double-blind study. Am J Gastroenterol 1995; 90: 423-30.
16. 16 Castell DO, Sigmund C, Patterson D, et al. Cisapride 20 mg bid provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. Am J Gastroenterol 1998; 93: 547-52.
17. 17 Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal disease in clinical practice: a clinical data base analysis. Gut 1998; 42: 13-6.
18. 18 Bloom AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis. A multinational placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993; 38: 551-60.
19. 19 Tytgat GMJ, Anker-Hansen OJ, Carling L, et al. Effect of cisapride on relapse of reflux esophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992; 27: 175-83.
20. 20 Hatleback JG, Johnson F, Vilien M, Karling L, Wetterhus S, Thogersen T. The effect of cisapride in maintaining symptomatic remission in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1997; 32: 110-6.
21. 21 Katschinski M, Ducre M, Wank U, Arnold R, Adler G. Comparison of cisapride and metoclopramide as esophageal prokinetics in healthy humans. Eur J Gastroenterol Hepatol 1993; 5: 677-82.
22. 22 Katschinski M, Wank U, Ducre M, Schirra J, Arnold R. Cisapride stimulates human esophageal motility. Digestion 1995; 56: 153-8.
23. 23 Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600-5.
24. 24 Gilbert RJ. Dodds RJ. Kahrilas PJ. Hogan WJ. Lipman S. Effect of cisapride a new prokinetic agent on esophageal motor function. Dig Dis Sci 1987; 32: 1931-6.
25. 25 Inauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and esophageal motility in patients with reflux esophagitis: a 24 h ambulatory combined pH and manometry study. Gut 1993; 34: 1025-31.
26. 26 Smith A, Bird NC, Troy GP, Globe J, Johnson AG. Effect of cisapride on oesophageal motility and dudenogastro-oesophageal reflux in patients with Barren's oesophagus. Eur J Gastroenterol Hepatol 1997; 9: 1149-53.
27. 27 Kahrilas PJ. Dodds WJ. Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology 1988; 94: 73-80.
28. 28 Russell COH, Bright N. What is the effect of cisapride on manometric pressure and propulsive force in the smooth muscle portion of the esophagus? In: Giuli R, McCallum RW, Skinner DB, eds. Primary Motility Disorders of the Esophagus. Paris: John Libbey Eurotext, 1991: 1111-7.
29. 29 Schoemann MM, Tippett MD, Akkermans LMA, Dent J, Holloway RH. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995; 108: 83-91.
30. 30 Pattel R, Lanspack J, Soffer E. Effects of cisapride on salivary production in normal subjects. Dig Dis Sci 1996; 41: 480-4.
31. 31 Boldin GF, Marcinkiewicz M, Zbroch T, Bityutskiy LP, McCallum RW, Sarosiek J. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal disease. Dig Dis Sci 1997; 42: 1362-9.
32. 32 Holloway RH, Downton J, Mitchell B, Dent J. Effect of cisapride on postprandial gastroesophageal reflux. Gut 1989; 30: 1187-93.
33. 33 Dent J, Holloway RH, Touuli J. Dodds WJ. Mechanisms of lower esophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 1988; 29: 1020-8.
34. 34 Pouderoux P, Kahrilas PJ. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in crosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 661-6.